Olanzapine. Pharmacokinetic and pharmacodynamic profile.
about
Treating nausea and vomiting in palliative care: a reviewReview of olanzapine in the management of bipolar disordersWeight loss dynamics during combined fluoxetine and olanzapine treatmentEffects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized ratsAntipsychotic dosing: found in translationThe antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouseApplication of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with SchizophreniaA current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.Summary of information on human CYP enzymes: human P450 metabolism data.Controlled release matrix tablets of olanzapine: influence of polymers on the in vitro release and bioavailability.Olanzapine: another psychotropic?Pharmacokinetics of olanzapine long-acting injection: the clinical perspective.Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patientsHuman alpha-1-glycoprotein and its interactions with drugs.Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study.Cytochrome P450 polymorphisms and response to antipsychotic therapy.Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters.The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine.Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.Interactions between the cytochrome P450 system and the second-generation antipsychotics.Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine.Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.Sex-dependent modulation of treatment responseClinical pharmacology of atypical antipsychotics: an update.Sex and age differences in the pharmacokinetics of alosetron.Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects.Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypesComparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalentsDevelopment and validation of an HPLC-UV method for the simultaneous determination of the antipsychotics clozapine, olanzapine and quetiapine, several beta-blockers and their metabolites.Omics Screening for Pharmaceutical Efficacy and Safety in Clinical PracticeOlanzapine: a 5-year perspective.Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents.Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways.Antipsychotic-induced increase in lipid biosynthesis: activation through inhibition?Metabolic drug interactions with newer antipsychotics: a comparative review.Alterations in drug disposition during pregnancy: implications for drug therapy.Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms.Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility.Pharmaceutical studies on and clinical application of olanzapine suppositories prepared as a hospital preparation.Delirium and extrapyramidal symptoms due to a lithium-olanzapine combination therapy: a case report.
P2860
Q24635649-DDCFF0FD-E9C9-4B99-8657-599CDF79E942Q24657398-57A3DA1F-4F63-4362-A2D8-5E4DB99F5B3CQ24794172-88233D07-5CD5-4DE3-A828-FDB94B71D7AFQ24805130-1835ACE1-8920-49AF-900E-91E79C5B6754Q26863343-6905A133-6F75-4466-B7DA-A02B3B5610ABQ28542712-4F63AE3B-2D0C-4982-8BCE-602E2BDE8017Q28550024-F8D49352-DE13-46BC-A9C2-24D13C6DCDADQ30667146-F290117C-60C2-466A-B661-B4D9BE71828FQ32103802-DEDA8F90-6FE7-4F5B-B3C4-EBD10FF79E34Q34280238-D17CC0B4-64A3-488C-B110-1CB2089AD25DQ34283153-C95D6634-1C20-4712-9F84-4F6E97865E91Q34293855-B8F5F440-E19C-4959-9528-A94929FFBE36Q34329829-8D864F5B-1FD5-4DA0-8F11-CB28A8F5D3D1Q34331335-02849C0D-1AAE-487C-813A-AE2B70CFA8A7Q34574179-919B63F6-78EE-42EC-A839-36FF098440A4Q34612118-0DE72CFB-BC77-4D8C-A7E6-122AD7CFE882Q34761472-E892C66D-9425-4DAB-9B23-24E748A450FCQ34830210-A2179FD6-AFED-4861-888A-243D6304648DQ35000771-EADC1BB2-5DD9-47AA-9350-CCB7943C50EFQ35096587-52B6697C-A845-49CF-87D8-B575228B06C9Q35111188-958F39ED-DA2B-4F52-9569-0A0CC3C78F96Q35206798-B283056C-078E-4832-A6B4-DB6B17A262F6Q35236761-E87FE089-E08C-4939-BCFF-478EBB26C323Q35728228-9DB582D0-6C10-4B8D-9C60-3A49365A6FCBQ35803732-86B434DD-3ED9-44D6-BD15-8ADFAFECB579Q35825477-360D42D5-6809-4DAE-A125-300CF01F2A2EQ35826075-3FA12EC6-72F6-4AC5-BB20-EF229DEDE4CEQ36235106-777ED065-930C-4009-A201-1AE187AC726FQ36299177-24942568-FFFC-4C14-996B-1252215A649FQ36477760-805FDB16-9351-43C7-9337-EA1684FB5D52Q36511290-ABD39CB7-0111-49EF-8BAC-27FE7B258815Q36522045-B3A37E8C-6C99-4AD3-87DF-62401EAFCD61Q36593819-41F99DD1-4A12-4D0C-BFC6-BC393F3B4E4CQ36658336-047BD457-6078-41D3-863B-5B21424D527CQ36703845-F664EEB9-9399-4AF8-BFC8-89EBF4FD56ECQ36909328-DD4F50A2-11E4-46F5-8A42-8978C0F11B36Q37157901-B432521A-8314-42F6-9BA4-6A65706A11D1Q37256691-29F3C00D-DE1E-429E-BB74-6306AF4FDF19Q37271895-CC3C73C7-D621-400D-AC74-0301DB084735Q37433784-671273D9-3EEC-4C4B-8CB4-FCA39B130331
P2860
Olanzapine. Pharmacokinetic and pharmacodynamic profile.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Olanzapine. Pharmacokinetic and pharmacodynamic profile.
@ast
Olanzapine. Pharmacokinetic and pharmacodynamic profile.
@en
type
label
Olanzapine. Pharmacokinetic and pharmacodynamic profile.
@ast
Olanzapine. Pharmacokinetic and pharmacodynamic profile.
@en
prefLabel
Olanzapine. Pharmacokinetic and pharmacodynamic profile.
@ast
Olanzapine. Pharmacokinetic and pharmacodynamic profile.
@en
P2093
P1476
Olanzapine. Pharmacokinetic and pharmacodynamic profile
@en
P2093
J T Callaghan
R F Bergstrom
P304
P356
10.2165/00003088-199937030-00001
P577
1999-09-01T00:00:00Z
P6179
1035394480